COSTA MESA, Calif., Feb. 12, 2015 /PRNewswire-iReach/ -- WCCT Global, a full service contract research organization (CRO) headquartered in Southern California, announced the certification of its laboratory staff in the technique for Peripheral Blood Mononuclear Cell (PBMC) Isolation. In the wake of recently announced collaborations with the National Institute of Allergy and Infectious Diseases (NIAID) and the Nolan Laboratory at the Stanford School of Medicine, WCCT Global has recognized the need to routinely isolate PBMCs to characterize the human immune response to disease and various immune-targeted therapeutic agents.
Photo - http://photos.prnewswire.com/prnh/20150212/175157
WCCT-Global’s facilities in Cypress and Costa Mesa, California, are equipped for research with healthy subjects (Cypress) and patients undergoing treatment (Costa Mesa) for viral illnesses or various immune therapies. WCCTG technical staff is equipped to collect a variety of high quality longitudinal samples providing data to help characterize drug response to therapy or the course of an illness without utilizing any treatment (influenza challenge). Isolation of PBMCs is often the obligatory 1st step for studies of immunological responses to various therapies. The isolated PBMCs can be used fresh for key research protocols or they can be cryopreserved and maintain high viability post-thaw.
Dr. Mel Affrime, Sr. VP Translational Medicine, WCCT Global said “We are confident that by incorporating PBMC isolation as a routine laboratory procedure our clients will understand how committed we are to supporting the full breadth of their research needs”.
More about WCCT Global:
WCCT Global is a multi-site, full service global contract research organization (CRO) of outsourced early drug development and late phase services to the pharmaceutical, biotechnology and medical device industries. The WCCT Global vision, “With compassion for people, we strive for tomorrow’s therapies to be available today” truly exemplifies the focus and reason for our cutting edge work both in our clinics and throughout our operations. As a drug development partner, WCCT Global collaborates with domestic and foreign innovator companies who need regulatory, program management, data management and strategic consulting support, with an emphasis on overseeing and executing trials in special disease populations, pediatric populations, ethno-bridging, and cardiac safety. WCCT has extensive experience with healthy volunteer studies including First-in-Human (FIH), as well as specific therapeutic expertise in Allergy, Asthma, HCV, Ophthalmology, Oncology, Renal, and Vaccines.
Media Contact:Matt Miller, WCCT Global, 714.668.1500 ext.2029, Matt.Miller@wcct.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE WCCT Global
Help employers find you! Check out all the jobs and post your resume.
